Bortezomib Accord 3.5 mg powder for solution for injection

DRUG3 trials

Sponsors

Oslo University Hospital HF, Karyopharm Therapeutics Inc., Universitair Medisch Centrum Groningen

Conditions

Multiple myelomaPenta-refractory multiple myeloma and triple-class refractory multiple myelomarelapsed/refractory multiple myeloma

Phase 2

A Phase 2b, Open-label, Multi-arm Clinical Trial of Selinexor Plus Low-dose Dexamethasone (Sd) in Patients with Penta-refractory Multiple Myeloma or Selinexor and Bortezomib Plus Low-dose Dexamethasone (SVd) in Patients with Triple-class Refractory Multiple Myeloma

RecruitingCTIS2024-511608-18-00

Karyopharm Therapeutics Inc.Penta-refractory multiple myeloma and triple-class refractory multiple myeloma

Start: 2020-06-25Target: 55Updated: 2025-10-08

RElapse from Mrd Negativity As iNdication for Treatment

Active, not recruitingCTIS2023-510215-18-00

Oslo University Hospital HFMultiple myeloma

Start: 2024-09-26Target: 391Updated: 2025-11-07

Phase 3

HO183 CAR T: A phase III randomized trial comparing academically produced BCMA-directed CAR T-cells (ARI0002h) with standard of care regimen in patients with relapsed/refractory multiple myeloma

Not yet recruitingCTIS2025-524876-43-00

Universitair Medisch Centrum Groningenrelapsed/refractory multiple myeloma

Target: 126Updated: 2026-04-29